Supplementary Methods

X-chromosomal genotyping, imputation, and quality control (QC)

For genotypes on the X chromosome, QC for non-pseudoautosomal regions markers was performed separately for male and female subjects. SNPs were excluded with MAF below 1% in the female group, genotyping rates below 98%, deviations from HWE in control individuals ($p<1\times10^{-4}$), differential genotyping efficiency between women and men ($p<1\times10^{-4}$), differential allele frequency between women and men ($p<1\times10^{-4}$) or ambiguous allele combinations (A/T and C/G). Markers in the pseudoautosomal regions (PAR1, PAR2) were processed analogous to the autosomes. We then aligned the alleles of the remaining SNPs to the reference genome "GRCh37/hg19" before imputation. Imputations of untyped X-Chromosomal markers (including PAR) were subsequently performed on the Sanger Institute imputation server (https://imputation.sanger.ac.uk/) using the extended HRC reference panel available at that site.¹ After imputation, we used the same QC criteria as for the autosomal SNPs on markers in PAR. For remaining non-PAR markers SNPs were excluded with MAF below 1% in male and female separately, imputation quality ($R^2<0.30$) and deviations from HWE ($p<5\times10^{-4}$).

Multiple testing adjustment

To strike a balance between reliable inference and power, we present our findings as primary, secondary and tertiary results. The primary analyses in this study were the GWAS in the full dataset independent of sex. For SNP-based tests we applied the conventional genome-wide association threshold of p<5*10⁻⁸ and for gene-based tests we used Bonferroni's method to adjust for 19,511 genes resulting in a threshold

of p<2.3*10⁻⁶, as recommended by FUMA. The sex-specific analyses present additional tests of related (and non-independent) hypothesis, and, thus should be regarded as secondary and more exploratory analyses.

Next, we aimed to better understand the potential consequences of identified loci on latent AD and selected them for further mediation analyses. Here, we assume that the genome-wide significant SNPs are truly associated with a biomarker PC and test the hypothesis, that they are also associated with latent AD. As each SNP can be associated with latent AD either directly or via any of the five biomarker PCs, we adjusted for 6 possible pathways, resulting in a Bonferroni-adjusted alpha of 0.05/6=p<0.0083.

In case of comparisons to rare variants, we tested SNPs based on prior evidence of rare variants associations. We therefore only adjusted for number of SNPs within the selected loci. To account for non-independence between SNPs, we adjusted for the number of effective tests, taking into account the eigenvalue of correlation between SNPs. We estimated the number of effective tests using the Li & Ji method², as implemented in poolR³. In the current study, we assessed 564 SNPs within *IFFO1*, *DTNB*, *NLRC3* and *SLC22A10* for association with the injury/inflammation component (PC3). The estimated number of effective tests was 127, resulting in a Bonferroni-adjusted alpha of $0.05/127=3.9*10^{-4}$. In case of *GABBR2* and *CASZ*, which were tested for association with non-AD synaptic functioning (PC5), we analyzed 1837 common genetic variants within both genes, 312 of which were independent resulting in a Bonferroni adjusted alpha of $p<0.05/312=1.6*10^{-4}$.

References

1. McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang, H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. *48*, 1279–1283.

2. Li, J., and Ji, L. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). *95*, 221–227.

3. Cinar, O., and Viechtbauer, W. meff: Number of Effective Tests.



Figure S1: QQ-plots of SNP test statistics. Diagonal line indicates a p-value distribution expected by chance. Dots represent p-values per SNP for each of the outcomes (see legend for color coding). Each panel depicts the p-value distribution for different GWAS models, either main effects (all sexes), male or female-stratified, or the p-values of a sex interaction term.



Figure S2: Manhattan plot (sex interaction). Sex-interaction results from GWAS of five CSF biomarker PC. Each row represents a different PC as outcome. X-axis represents each SNP and the y-axis the p-value of the sex-interaction term on a - log_{10} scale. All analyses were adjusted for genetic ancestry and SNP array. Red line indicates genome-wide significance threshold (p=5*10⁻⁸). Yellow line indicates suggestive threshold (p=1*10⁻⁶). Vertical lines point towards genome-wide significant loci based on any model. P-values below 1*10⁻¹⁰ were winsorized to 1*10⁻¹⁰



Figure S3: Manhattan plot (gene-based tests). Results from GWAS of five CSF biomarker PC across both sexes. Each row represents a different PC as outcome. X-axis represents each SNP and the y-axis the p-value of the gene-based association derived with MAGMA on a $-\log_{10}$ scale. All analyses were adjusted for sex, genetic ancestry, and SNP array. Red line indicates genome-wide significance threshold (p=2.3*10⁻⁶). Yellow line indicates suggestive threshold (p=1*10⁻⁴). Vertical lines point towards genome-wide significant loci based on any model. P-values below 1*10⁻¹⁰ were winsorized to 1*10⁻¹⁰.

	EMIF (n=769)					ADNI (n=389)						
		Male (n=3 ⁻	70)		Female (n=	399)		Male (n=2	231)		Female (n	=158)
Characteristic	n	Mean/%	SD	n	Mean/%	SD	n	Mean/%	SD	n	Mean/%	SD
Age	370	68.84	8.54	399	69.76	8.16	231	75.37	7.02	158	73.89	7.18
Education (in years)	370	11.77	3.73	399	10.24	3.61	231	16.11	3.07	158	14.89	2.81
Diagnosis												
Cognitively normal	31	8.4%	-	44	11.0%	-	55	23.8%	-	55	34.8%	-
Subjective cognitive impairment	37	10.0%	-	27	6.8%	-	0	0	-	0	0%	-
Mild cognitive impairment	215	58.1%	-	234	58.6%	-	123	53.2%	-	62	39.2%	-
Alzheimer's disease	87	23.5%	-	93	23.3%	-	53	22.9%	-	41	26.0%	-
Mini-mental state examination	369	25.94	3.61	158	25.16	4.21	231	26.68	2.54	158	26.79	2.68
CSF biomarkers												
β-Amyloid₄₂ (in pg/ml)	369	324.71	198.80	397	1140.84	2242.28	231	874.81	440.57	158	951.68	455.24
Tau (in pg/ml)	368	359.07	305.75	397	405.16	364.22	231	294.22	122.39	158	296.61	148.87
Phosphorylated Tau (in pg/ml)	369	57.74	32.71	399	61.93	35.13	231	28.98	14.15	158	28.74	15.87
Neurofilament light (in pg/ml)	366	1306.58	1920.92	395	1140.84	2242.28	231	1582.10	1160.31	158	1277.99	527.32
YKL-40 (in pg/ml or z-score*)	370	171469.09	64960.25	398	173950.23	65679.59	52	0.17	0.97	34	-0.09	0.89
Neurogranin (in pg/ml)	333	136.74	196.51	158	147.84	153.24	231	440.00	356.00	158	436.51	307.58

Table S1: Participant Characteristics CSF Biomarker Sample

Table 1: Participant characteristics. Demographic information and descriptive statistics for participants with information on at least four biomarkers.

n Sample size

SD Standard Deviation

* For ADNI, average values of two peptide sequences, with two ion frequencies each, were averaged after z-score standardization

	EMIF (n=672)					ADNI (n=301)						
		Male (n=3	22)		Female (n=	350)		Male (n=1	.83)		Female (n	=118)
Characteristic	n	Mean/%	SD	n	Mean/%	SD	n	Mean/%	SD	n	Mean/%	SD
Age	322	68.85	8.52	350	70.05	8.15	183	75.38	6.79	118	73.91	7.33
Education (in years)	322	11.90	3.66	350	10.34	3.61	183	15.71	3.01	118	15.97	2.99
Diagnosis												
Cognitively normal	27	9.9%	-	23	10.6%	-	43	23.5%	-	43	36.4%	-
Subjective cognitive impairment	32	8.4%	-	37	6.6%	-	0	0%	-	0	0%	-
Mild cognitive impairment	190	59.0%	-	210	60.0%	-	96	41.6%	-	50	42.4%	-
Alzheimer's disease	73	22.7%	-	80	22.9%	-	44	19.0%	-	25	21.2%	-
Mini-mental state examination	321	25.87	3.65	349	25.17	4.23	183	26.72	2.47	118	27.14	2.63
CSF biomarkers												
β-Amyloid₄₂ (in pg/ml)	322	316.29	196.75	348	298.63	177.71	183	819.00	441.05	118	893.79	451.59
Tau (in pg/ml)	320	370.51	309.19	348	415.34	376.82	183	304.36	118.37	118	314.37	148.90
Phosphorylated tau (in pg/ml)	321	59.05	32.90	250	62.59	35.87	183	29.81	13.40	118	30.81	16.19
Neurofilament light (in pg/ml)	318	1247.64	1736.51	346	1173.67	2386.09	183	1554.11	1247.24	118	1285.79	811.96
YKL-40 (in pg/ml or z-score*)	322	169938.49	64617.47	349	174465.75	66691.41	41	0.13	1.01	32	-0.18	1.01
Neurogranin (in pg/ml)	289	136.72	196.75	329	149.32	157.89	183	469.03	297.35	118	504.47	306.39

Table S2: Participant Characteristics GWAS Sample

 Table 2: Participant characteristics.
 Demographic information and descriptive statistics for main GWAS analysis sample.

n Sample size

SD Standard Deviation

* For ADNI, average values of two peptide sequences, with two ion frequencies each, were averaged after z-score standardization

Table S3: Sex differences in CSF biomarker PCs and associations with Alzheimer's disease

Outcome	Predictor	β	SE	р
Sex differences in mean levels				
Tau pathology/Degeneration	Female	0.14	0.06	1.74E-02
Injury/Inflammation	Female	-0.01	0.06	8.04E-01
Injury/Inflammation	Female	-0.40	0.05	2.66E-13
Non-AD Inflammation	Female	0.02	0.06	7.88E-01
Non-AD Synaptic Functioning	Female	0.21	0.06	6.37E-04
Latent AD regressed on PCs an				
Latent AD	Female	0.05	0.07	4.75E-01
Latent AD	Tau pathology/Degeneration	0.41	0.05	6.83E-17
Latent AD	Tau pathology/Degeneration*Female	0.01	0.07	8.56E-01
Latent AD	Aβ Pathology	-0.34	0.05	1.09E-12
Latent AD	Aβ Pathology*Female	-0.11	0.07	1.33E-01
Latent AD	Injury/Inflammation	0.40	0.06	2.75E-12
Latent AD	Injury/Inflammation*Female	0.05	0.07	5.12E-01

Latent AD	Non-AD Inflammation	0.12	0.05	1.94E-02
Latent AD	Non-AD Inflammation*Female	0.04	0.07	5.70E-01
Latent AD	Non-AD Synaptic Functioning	0.04	0.05	4.17E-01
Latent AD	Non-AD Synaptic Functioning*Female	-0.12	0.07	1.02E-01

Table 4: Sex differences in CSF biomarker PCs and associations with Alzheimer's disease.

Rows 2-7 represent linear models, in which CSF Biomarker PCs are regressed on sex (Male=0, Female=1), adjusted for age, study and genetic ancestry components. Each outcome is fitted in a separate model. β represents the covariate adjusted difference in mean levels between females and males.

Rows 9-19 represents a structural equation model in which a latent AD factor is regressed on sex, biomarker PCs, the interaction between sex and Biomarker PCs, as well as age, study and genetic ancestry components. **β** represents either the effect of being female on latent AD in SD assuming mean PC levels (Female), the effect of biomarker PCs on latent AD in males (biomarker PC), and the additional effect of the biomarker for females (biomarker PC*Female).

SE Standard Error

p p-value